Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance.

about

Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.Ensuring the Safety and Security of Frozen Lung Cancer Tissue Collections through the Encapsulation of Dried DNA.

P2860

Q55314894-60311111-0CE6-471F-9C17-887B7CC49021 Q55454963-F27E42A1-B02A-4F0B-9C7D-FDFC3EAD092B

P2860

Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance.

Item

http://www.wikidata.org/entity/Q46071509

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Emerging uses of biomarkers in ...... ular mechanisms of resistance.

@en

Emerging uses of biomarkers in ...... ular mechanisms of resistance.

@nl

type

Item

label

Emerging uses of biomarkers in ...... ular mechanisms of resistance.

@en

Emerging uses of biomarkers in ...... ular mechanisms of resistance.

@nl

prefLabel

Emerging uses of biomarkers in ...... ular mechanisms of resistance.

@en

Emerging uses of biomarkers in ...... ular mechanisms of resistance.

@nl

P1476

Emerging uses of biomarkers in ...... ular mechanisms of resistance.

@en

P2093

Balazs Halmos

http://www.w3.org/2001/XMLSchema#string

Numa Rahman

http://www.w3.org/2001/XMLSchema#string

Shirin Attarian

http://www.w3.org/2001/XMLSchema#string

P2860

Liquid biopsies: genotyping circulating tumor DNA

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

P304

377

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/ATM.2017.07.18

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29057237

http://www.w3.org/2001/XMLSchema#string

P932

5635262

http://www.w3.org/2001/XMLSchema#string

Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance.

about

P2860

P2860

Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932